Financial advisors are adding value by expanding their focus to include private markets. From an investing perspective, ...

Next-generation AI-powered devices and experiences to be showcased at the company's exclusive exhibition through January 7 ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a ...